Business
Altimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022
GAITHERSBURG, Md., March 08, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will
About this update from Altimmune, Inc.
[{"type":"text","content":"GAITHERSBURG, Md., March 08, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2021 financial results on Tuesday, March 15, 2022. Altimmune management will host a conference call at 8:30 am E.T. on March 15 to discuss financial results and provide a business update. Conference Call Information: Date:Time:Domestic Dial-in:International Dial-in:Conference ID:Webcast:Tuesday, March 158:30 am Eastern Time(844) 615-6509(918) 922-31484557398https://edge.media-server.com/mmc/p/5www3cgz About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com. Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter Investor and Media Contact: Richard EisenstadtChief Financial OfficerPhone: [email protected] \nSource: Altimmune, Inc","length":4381,"tagName":"div"}]